First United States Experience With Focal Pulsed‐Field Ablation Using the FARAPOINT Catheter for Refractory Ventricular Tachycardia
Journal of Cardiovascular Electrophysiology · 2026
DOI: 10.1111/jce.70498 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cardiovascular Electrophysiology, 2026. Verfasst von Jorge L Reyes und 3 weiteren Autor:innen. Beteiligte Einrichtung: Cardiac Electrophysiology Section, Minneapolis VA Health Care System and University of Minnesota Medical School, Minneapolis, Minnesota, USA. Hauptthemen laut MEDLINE: Tachycardia, Ventricular, Cardiac Catheters, Heart Rate, Catheter Ablation. Die Arbeit nennt 6 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Drug‐refractory ventricular tachycardia (VT) after failed radiofrequency (RF) ablation remains a clinical challenge. Pulsed‐field ablation (PFA) is expanding to ventricular applications, but United States experience with focal pulsed‐field‐only catheters in VT is sparse, and pulsed‐field platforms are not equivalent across manufacturers. Here we describe the first United States experience of FARAPOINT focal PFA in patients with refractory VT. Methods and Results We retrospectively reviewed ten consecutive patients who underwent VT ablation with the FARAPOINT (Boston Scientific) focal PFA catheter at a single VA Health Care System between July 2025 and May 2026. All patients had drug‐refractory sustained monomorphic VT. Median age was 77 years with a mix of ischemic and nonischemic cardiomyopathy. Six of ten had at least one prior failed catheter ablation. Acute non‐inducibility was achieved in all nine patients who underwent formal post‐ablation stimulation testing. No procedural complications occurred. Over a median follow‐up of 95.5 days, sustained VT recurred in four of ten patients. No patient underwent repeat ablation, required mechanical circulatory support, or died.
Conclusions
In this initial United States experience, FARAPOINT was safe and acutely effective in patients with ischemic cardiomyopathy within a high‐risk cohort with refractory VT and prior failed ablations, including challenging substrates. Prospective multicenter studies are warranted to expand these observations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Cardiac Electrophysiology Section, Minneapolis VA Health Care System and University of Minnesota Medical School, Minneapolis, Minnesota, USA.
ORCID-Profile: Jorge L Reyes, Rezwan Munshi, Collin Goebel, Venkat Tholakanahalli
Zitieren
APA
Reyes, J. L., Munshi, R., Goebel, C., & Tholakanahalli, V. (2026). First United States Experience With Focal Pulsed‐Field Ablation Using the FARAPOINT Catheter for Refractory Ventricular Tachycardia. Journal of Cardiovascular Electrophysiology. https://doi.org/10.1111/jce.70498
Vancouver
Reyes JL, Munshi R, Goebel C, Tholakanahalli V. First United States Experience With Focal Pulsed‐Field Ablation Using the FARAPOINT Catheter for Refractory Ventricular Tachycardia. Journal of Cardiovascular Electrophysiology. 2026. doi:10.1111/jce.70498
BibTeX
@article{Reyes2026,
author = {Reyes, Jorge L and Munshi, Rezwan and Goebel, Collin and Tholakanahalli, Venkat},
title = {First United States Experience With Focal Pulsed‐Field Ablation Using the FARAPOINT Catheter for Refractory Ventricular Tachycardia},
journal = {Journal of Cardiovascular Electrophysiology},
year = {2026},
doi = {10.1111/jce.70498}
}
EUVIMED